.Nature Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after a mean follow-up of 11 months, clients along with metastatic gastrointestinal lumps who obtained biomarker-matched therapies based upon distributing growth DNA profiling showed a higher medical advantage than those getting unparalleled therapy.